How did COLL's Q4 earnings surprise impact investor sentiment?

Collegium Pharmaceutical's (COLL) Q4 earnings report exceeded investor expectations, reflecting positively on investor sentiment.

1. **Earnings Surprise**: Collegium reported an actual EPS of $1.75 for Q4 2024, compared to the estimated EPS of $1.66. This indicates a positive earnings surprise, as the company's performance exceeded expectations.

2. **Revenue Outperformance**: The actual revenue for the quarter was $181.9 million, surpassing the estimated revenue of $179.48 million. This suggests that Collegium generated more revenue than anticipated.
3. **Market Reaction**: Despite being slightly overvalued by some analysts, the positive earnings surprise likely contributed to investor confidence. The company's focus on growing its pain portfolio and the addition of Jornay PM in neuropsychiatry may have also bolstered investor sentiment.
4. **Future Outlook**: The company's reaffirmation of full-year 2025 guidance and the successful execution of share repurchases in 2024 could further enhance investor confidence in Collegium's future performance.

In conclusion, Collegium's Q4 earnings report, with its positive earnings surprise and revenue outperformance, is likely to have had a positive impact on investor sentiment, potentially leading to increased confidence in the company's growth prospects.